Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts

AbbottAbbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Texas and Louisiana. The Abbott Fund is providing $900,000 in grants to the American Red Cross, Americares and Direct Relief. Abbott is donating $100,000 in healthcare and nutrition products to relief organizations providing on-the-ground support in affected communities.

These donations build on earlier work with our partners Direct Relief and Feeding America to help communities prepare for the 2017 hurricane season. Abbott nutrition and healthcare products were stored at health clinics and food banks in advance of hurricane season, including in Louisiana and Texas. As a result, these clinics and food banks were able to quickly respond to meet immediate needs following Hurricane Harvey. For more information on our hurricane prep efforts, click here.

"Our thoughts are with everyone affected by Hurricane Harvey, and the many people and organizations working to help families in the affected communities," said Miles D. White, chairman and chief executive officer, Abbott. "Abbott and the Abbott Fund are working together with trusted relief organizations to help meet immediate needs today, and to help communities recover after the storm."

About Abbott and the Abbott Fund
As part of its commitment to helping people build better lives and stronger communities, Abbott has a long history of providing humanitarian relief around the world. Over the past decade, Abbott and its foundation the Abbott Fund have provided more than $40 million in funding and products to help meet both immediate needs and support long-term recovery efforts. In recent years, this included a rapid response to earthquakes in Chile, China and Haiti, typhoons in the Philippines and Vietnam, and hurricanes in the U.S.

At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...